HQL - Tekla Life Sciences Investors

NYSE - Nasdaq Real Time Price. Currency in USD
17.73
+0.15 (+0.85%)
As of 9:41AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close17.58
Open17.83
Bid17.39 x 800
Ask17.77 x 1100
Day's Range17.62 - 17.73
52 Week Range11.45 - 18.24
Volume8,497
Avg. Volume142,004
Market Cap416.563M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-3.04
Earnings DateN/A
Forward Dividend & Yield1.36 (7.59%)
Ex-Dividend DateMay 28, 2020
1y Target EstN/A
  • Business Wire

    Tekla Life Sciences Investors Declares Stock Distribution

    On May 18, 2020, Tekla Life Sciences Investors declared a stock distribution of $0.34 per share. The record date for the stock distribution is May 29, 2020 and the payable date is June 30, 2020. The Fund will trade ex-distribution on May 28, 2020.

  • Business Wire

    Tekla World Healthcare Fund Declares Monthly Cash Distribution

    On May 8, 2020, Tekla World Healthcare Fund declared its monthly cash distribution of $0.1167 per share. The record date for the monthly cash distribution is May 20, 2020 and the payable date is May 29, 2020. The Fund will trade ex-distribution on May 19, 2020.

  • Business Wire

    Tekla Healthcare Opportunities Fund Declares Monthly Cash Distribution

    On May 8, 2020, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is May 20, 2020 and the payable date is May 29, 2020. The Fund will trade ex-distribution on May 19, 2020.

  • Business Wire

    Tekla World Healthcare Fund Paid Distribution

    On April 30, 2020, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized losses on sale of securities is -$10,909,902, of which $5,296,272 represents net unrealized depreciation of portfolio securities.

  • Business Wire

    Tekla Healthcare Opportunities Fund Paid Distribution

    On April 30, 2020, Tekla Healthcare Opportunities Fund paid a monthly distribution of $0.1125 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $55,390,415, of which $54,955,447 represents net unrealized appreciation of portfolio securities.

  • Business Wire

    Tekla Life Sciences Investors Paid Distribution

    On March 31, 2020, Tekla Life Sciences Investors paid a distribution of $0.39 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $29,547,773, of which $10,156,073 represents net unrealized appreciation of portfolio securities.

  • Business Wire

    Tekla Healthcare Investors Paid Distribution

    On March 31, 2020, Tekla Healthcare Investors paid a distribution of $0.47 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains and net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is $36,078,563, of which $826,666 represents net unrealized depreciation of portfolio securities.

  • Business Wire

    Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program

    Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2020. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2021. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund’s shares and the net asset value per share. The share repurchase program is intended to increase the Fund’s net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.

  • MoneyShow

    Top Picks 2020- Tekla Life Sciences Fund HQL

    Tekla Life Sciences Fund (HQL) frequently makes the cut as my Top Pick for more conservative investors -- thanks to its generous distribution policy, explains Nate Pile, editor of Nate's Notes.